Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. QAAGZX: which is better?

Bottom line

XLV vs QAAGZX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 80% by weight.

But QAAGZX is far broader, holding 277 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.

XLV is cheaper at 0.08% vs 0.86% — a difference of $78 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +4.1% for QAAGZX.

Updated Nov 19, 2026

XLV vs QAAGZX side by side

XLVQAAGZX
TypeETFETF
Fund familySPDR (State Street)T. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%0.86%
Annual cost per $10k$8$86
10-yr cost on $10k (prospectus)$103$1,061
Max front loadNoneNone
12b-1 fee0.02%0%
1-yr return+14.5%+18.1%
5-yr return (annualized)+8.1%+4.1%
10-yr return (annualized)+9.8%+9.0%
Best quarter+14.5%+23.4%
Worst quarter−12.7%−15.8%
Net assets (fund)$40.6B$751.7M
Number of holdings65277
Portfolio turnover2%65%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVQAAGZXDifference
2025+14.5%+18.1%−3.6%
2024+2.5%+1.7%+0.8%
2023+2.0%+3.0%−1.0%
2022−2.1%−12.5%+10.4%
2021+25.9%+13.1%+12.8%
2020+13.3%+29.6%−16.4%
2019+20.7%+29.0%−8.3%
2018+6.3%+1.1%+5.2%
2017+21.7%+27.6%−5.9%
2016−2.8%−10.5%+7.7%

Source: Fund prospectus bar charts

Holdings overlap

17 of XLV's top 25 holdings also appear in QAAGZX's top 25.

Shared top holdings
HoldingXLVQAAGZX
Eli Lilly & Co16.51%14.06%
Johnson & Johnson10.64%6.64%
AbbVie Inc7.74%5.12%
UnitedHealth Group Inc6.57%5.88%
Merck & Co Inc5.52%4.00%
Amgen Inc3.40%1.80%
Thermo Fisher Scientific Inc3.24%2.53%
Abbott Laboratories2.75%1.91%
Gilead Sciences Inc2.73%2.79%
Intuitive Surgical Inc2.45%1.89%
CVS Health Corp2.30%0.93%
Vertex Pharmaceuticals Inc2.19%2.26%
Danaher Corp2.09%1.44%
Bristol-Myers Squibb Co2.05%2.12%
Stryker Corp1.89%1.78%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

QAAGZX top 10

  1. Eli Lilly & Co — 14.06%
  2. Johnson & Johnson — 6.64%
  3. Unitedhealth Group Inc — 5.88%
  4. Abbvie Inc — 5.12%
  5. Merck & Co. Inc. — 4.00%
  6. Gilead Sciences Inc — 2.79%
  7. Thermo Fisher Scientific Inc — 2.53%
  8. Vertex Pharmaceuticals Inc — 2.26%
  9. Bristol-myers Squibb Co — 2.12%
  10. Abbott Laboratories — 1.91%

FAQ

What is the difference between XLV and QAAGZX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 80% by weight. But QAAGZX is far broader, holding 277 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
Which is cheaper, XLV or QAAGZX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and QAAGZX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.